Table 1.

Baseline characteristics

Variables, Median (IQR) or N (%)SertralinePlacebo
Responders, n=31Nonresponders, n=66Responders, n=24Nonresponders, n=72
Demographic factors
 Age, yr59.0 (12.4)57.1 (15.4)58.4 (12.6)59.3 (12.2)
 Male sex25 (80.7)49 (74.2)21 (87.5)45 (63.4)a
 Race
  Black22 (71.0)34 (48.5)17 (70.8)38 (52.8)
  White9 (29.0)32 (48.5)7 (29.1)33 (45.8)
  Other0 (0.0)0 (0.0)0 (0.0)1 (1.4)
 Hispanic ethnicity4 (12.9)17 (25.8)2 (8.3)12 (16.7)
 Education >high school25 (80.7)48 (73.9)21 (87.5)58 (84.1)
 Married10 (34.5)23 (35.9)13 (56.5)24 (33.8)
 Lives alone10 (34.5)15 (23.4)5 (21.7)20 (28.2)
 Employed8 (27.6)12 (19.1)1 (4.4)10 (13.9)
Clinical factors
 CKD stage at randomization
  Stage 317 (54.8)29 (43.9)14 (58.3)30 (41.7)
  Stage 410 (32.3)24 (36.4)6 (25.0)30 (41.7)
  Stage 54 (12.9)13 (19.7)4 (16.7)12 (16.7)
 Charlson Comorbidity Index5.7 (1.7)6.0 (2.5)6.7 (3.0)6.1 (2.4)
 Hypertension31 (100.0)63 (96.9)24 (100.0)70 (97.2)
 Diabetes mellitus19 (61.3)39 (60.0)16 (66.7)39 (54.2)
 Coronary artery disease7 (22.6)15 (23.1)9 (37.5)12 (16.9)
 Congestive heart failure10 (32.3)21 (32.3)9 (37.5)22 (30.6)
 Cerebrovascular disease4 (12.9)13 (20.0)2 (12.5)10 (13.9)
 Peripheral vascular disease6 (19.4)11 (16.9)1 (4.2)9 (12.9)
 Liver disease2 (6.5)7 (10.9)3 (12.5)6 (8.6)
 Lung disease3 (10.0)11 (16.9)4 (16.7)10 (14.3)
 Cancer3 (9.7)10 (15.4)6 (25.0)9 (12.7)
 Drug abuse7 (24.1)13 (20.3)6 (25.0)17 (23.6)
 Alcohol abuse13 (44.8)23 (35.9)11 (45.8)32 (44.4)
 Tobacco use, current6 (20.7)14 (22.2)6 (27.3)16 (22.5)
Laboratory measurements
 eGFR, ml/min per 1.73 m230.0 (18.0–39.0)26.5 (16.0–35.0)35.0 (15.5–43.0)26.0 (17.0–33.5)
 ACR, mg/g803.5 (1171.7)1364.5 (2097.8)1089.9 (1313.3)1022.8 (1349.9)
 Hemoglobin, g/dl12.0 (1.9)11.9 (2.2)12.0 (2.2)12.0 (2.2)
 Albumin, g/dl3.8 (0.5)3.7 (0.7)3.8 (0.5)3.9 (0.5)
 Prealbumin, mg/dl30.1 (7.3)32.5 (8.4)29.1 (10.6)30.4 (8.1)
 hsCRP, mg/L5.0 (2.0–14.6)2.7 (0.8–6.0)b3.2 (1.3–9.1)3.7 (1.7–10.0)
 IL-6, pg/ml3.9 (2.5–7.0)3.7 (2.1–8.0)3.1 (2.3–6.8)4.1 (2.5–6.7)
  • Reference ranges: albumin, 3.0–5.0 g/dl; prealbumin, 20–40 mg/dl; hsCRP, 0.0–3.0 mg/L; and IL-6, 0.31–5.00 pg/ml. IQR, interquartile range; ACR, albumin-to-creatinine ratio; hsCRP, high-sensitivity C-reactive protein.

  • a P<0.05 for responders versus nonresponders in the placebo group.

  • b P<0.05 for responders versus nonresponders in the sertraline group.